Arash Matian, DO
Family Medicine · Sherman Oaks, CANPI 1558300582
Payments from drug & device makers
Across 270 payments — averaging $4535.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$356K
- Eli Lilly$333K
- Alnylam Pharmaceuticals Inc.$271K
- Endo Pharmaceuticals Inc.$70K
- GSK$60K
- Organon$48K
- plus $85K from 12 others
Across 2 payments — averaging $3477.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Travel & lodging$95064%
- Food & beverage$53836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 4 | $356,374 |
| Eli Lilly | 4 | $333,193 |
| Alnylam Pharmaceuticals Inc. | 195 | $270,996 |
| Endo Pharmaceuticals Inc. | 8 | $69,960 |
| GSK | 25 | $60,171 |
| Organon | 6 | $48,400 |
| Braintree Laboratories, Inc. | 2 | $29,825 |
| AbbVie(2 entities) | 11 | $27,528 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17,400 |
| Pfizer | 2 | $9,285 |
| Galderma Laboratories, L.p. | 1 | $1,204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Lilly USA, LLC | 2 | $27 |
| Medtronic | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Vertiflex, Inc. | 1 | $12 |
How this compares
$1,224,488 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 15 | $10,414 |
| Tamsulosin Hcl | 32 | $900 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $887 |
| Rosuvastatin Calcium | 35 | $747 |
| Metformin Hcl | 60 | $612 |
| Lisinopril | 48 | $433 |
| Trazodone Hcl | 37 | $431 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $400 |
| Atorvastatin Calcium | 80 | $380 |
| Finasteride | 22 | $374 |
| Gabapentin | 41 | $367 |
| Metoprolol Succinate | 23 | $353 |
| Pantoprazole Sodium | 29 | $325 |
| Amlodipine Besylate | 64 | $301 |
| Omeprazole | 28 | $268 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Sherman Oaks
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.